To elucidate the role of VEGFs/VEGF receptors in drug resistance, we conducted in vitro assays using lung cancer cell lines classified as sensitive or resistant based on VEGF/VEGF receptor (VEGFC, KDR, and NRP2) expression and IC50 values of anti‐VEGF drugs (cabozantinib, pazopanib, and sitravatinib). This evidence concerns the gene NRP2 and lung carcinoma.